Sage Journals: Discover world-class research

Abstract

Background

Chronic hand dermatitis (CHD) is difficult to treat and has high individual and societal burdens. Phototherapy and oral alitretinoin are safe monotherapies for CHD, but their combination has not been assessed.

Objective

To assess the effectiveness and safety of low dose oral alitretinoin combined with phototherapy versus high dose oral alitretinoin for CHD refractory to topical corticosteroids.

Methods

This retrospective study of adult patients with CHD refractory to topical corticosteroid therapy compared low dose oral alitretinoin (10 mg three times weekly) combined with narrowband ultraviolet B therapy (three times weekly; LDA-UVB) to high dose oral alitretinoin (30 mg daily; HDA) for 16 weeks. Outcomes were improvement in disease severity measured by the Physician’s Global Assessment and quality of life measured with the Dermatology Life Quality Index.

Results

The mean age of the study population (n = 64) was 41.25 years and 57.8% were male. Both cohorts experienced improvements in disease severity and quality of life after 16 weeks, however, significantly more participants who received LDA-UVB (n = 21/33, 63.6%) achieved “clear” or “almost clear” assessments compared to those who received HDA (n = 12/31, 38.7%; P < .05). Adverse effects were significantly more prevalent in the HDA group (P < .0001) and included headache, elevated cholesterol, and dry lips.

Conclusions

The combination of low dose oral alitretinoin with narrowband-UVB therapy was more effective and had fewer adverse effects compared to high dose oral alitretinoin for participants with CHD refractory to topical corticosteroid therapy.

Keywords

alitretinoin chronic hand dermatitis dyshidrotic eczema narrowband ultraviolet B phototherapy

Introduction

Chronic hand dermatitis (CHD) is an inflammatory non-infectious eruption of the hands that persists for more than 3 months or has at least two relapses within one calendar year.¹ CHD can be classified by its etiology or by its morphology into the following subtypes: hyperkeratotic hand dermatitis (HHD), dyshidrotic hand eczema (DHE), and fingertip dermatitis (FTD).^2,3 The prevalence of hand dermatitis is approximately 10% in the general population and it is estimated that between 5% to 10% of patients with hand dermatitis will develop CHD.^4,5 People with CHD have reduced quality of life (QOL), impaired psychosocial wellbeing, and increased absences from work.^6,7 The disease burden translates to society with associated healthcare costs and lost productivity.

The approach to treatment of CHD is stepwise and begins with moisturizers and emollients, avoidance of allergens and irritants, and application of moderate- to high-potency topical corticosteroids.¹ Approximately 50% to 60% of patients with CHD will not respond to these treatments.^8
-10 There are limited options for CHD refractory to topical corticosteroids. Alitretinoin (9-cis retinoic acid) is an endogenous retinoid that was approved for the treatment of severe CHD that does not respond adequately to potent topical corticosteroids by the European Medicines Agency in 2008 and by Health Canada in 2010.^11,12 Oral alitretinoin received approval after a randomized double-blind placebo-controlled multicentre phase-III trial (BACH) in Canada and Europe of n = 1,032 patients with severe refractory CHD demonstrated its efficacy and safety.² Forty-eight percent of participants treated with 30 mg of oral alitretinoin once daily for 24 weeks achieved Physician Global Assessment (PGA) scores of “clear” or “almost clear” compared to 17% who received placebo (P < .001).² Another pivotal multicentre clinical trial (HANDEL) confirmed oral alitretinoin was effective in reducing the severity of CHD.³ Treatment with alitretinoin was associated with a significantly faster time to response than placebo (P < .001) and had a significantly positive effect on QOL.³ Evidence from real-world use is consistent with these findings.^12
-14 Common adverse effects occurring in >5% of patients include headache, increased cholesterol and triglyceride levels, mucocutaneous events, and decreased thyroid-stimulating hormone (TSH). These effects are dose-dependent and occur more frequently in participants who receive higher doses.^2,15 Between 5% and 10% of participants in the literature have withdrawn from treatment due to adverse effects or clinically relevant changes of laboratory values.^2,3,12,15

Phototherapy is an alternative treatment for CHD refractory to topical corticosteroids.^1,16 Controlled trials of ultraviolet A (UVA), psoralen-plus UVA (PUVA), UVB, and narrowband-UVB (NB-UVB) for the treatment of CHD determined that NB-UVB had the fewest side effects and comparable efficacy.^17

-20 Unfortunately, phototherapy of any kind is only modestly effective, with response rates ranging from 8% to 40%.^21
-23

The evidence to treat CHD refractory to topical corticosteroid therapy is inadequate and limited.²³ The combination of oral retinoids with ultraviolet therapy (Re-UV) has been available as a treatment modality for other cutaneous conditions for almost half a century. Despite evidence in psoriasis and cutaneous T-cell lymphoma, Re-UV remains an underutilized therapeutic modality.²⁴ In both of these conditions, Re-UV was found to be more effective and had fewer adverse effects than either monotherapy. The objective of this retrospective cohort study was to assess the effectiveness and safety of low dose oral alitretinoin (10 mg three times weekly) in combination with narrowband ultraviolet B therapy (three times weekly; LDA-UVB) relative to high dose alitretinoin (30 mg daily; HDA) administered for 16 weeks for the treatment of CHD refractory to topical corticosteroids.

Methods & Patients

Study Design

This study was approved by the institutional review board. A retrospective review of electronic medical records was conducted for adult patients (>18 years of age) with CHD refractory to topical corticosteroids and treated with LDA-UVB or HDA from 2017 to 2020.

Participants

Patients with HHD, DHE, and FTD were included. Eligible participants were required to i) meet formal criteria for CHD (persistent for at least 3 months, or with two or more flares within one calendar year); ii) have tried potent topical corticosteroids (clobetasol propionate 0.05% ointment daily for 3 weeks, then 1 week off) for at least 8 weeks; and iii) have failed to respond or were unable to achieve remission with topical corticosteroids.

Interventions

The HDA group received the recommended dose of 30 mg of oral alitretinoin daily. The LDA-UVB group received 10 mg of oral alitretinoin on Mondays, Wednesdays and Fridays, with NB-UVB therapy delivered on the same days. Participants were started on oral alitretinoin and NB-UVB simultaneously. The initial starting dose of NB-UVB was 75% of the recommended dose based on Fitzpatrick skin type. All participants provided informed consent after a thorough discussion of the risks and benefits associated with either treatment. Female participants of child-bearing age were required to start two methods of contraception. Treatment duration was 16 weeks for both cohorts with follow up every 4 weeks. Participants were instructed to use only moisturizers concurrently.

Outcome Measures and Statistical Analyses

The primary outcome was response to treatment, defined as achieving a rating of “clear” or “almost clear” (scores of 0 or 1, respectively) on the PGA after 16 weeks of treatment. The PGA is a measure of disease severity scored on a Likert scale from zero to four. A PGA score of 2 indicates mild disease, a score of 3 indicates moderate disease, and a score of 4 indicates severe disease. The secondary outcome was an improvement in QOL, defined as an at least 50% reduction in the Dermatology Life Quality Index (DLQI) after 16 weeks of treatment. The DLQI is a patient-reported measure of the impact their skin condition has on QOL. The index is scored from zero to 30 and higher scores indicate a greater burden of disease; scores between 0-1 indicate no impact, scores 2-5 indicate a small impact, scores 6-10 indicate a moderate impact, scores 11-20 indicate a very large impact, and scores 21-30 indicate an extremely large impact. The proportion of participants who experienced an improvement in their QOL and the percent reduction in DLQI scores were measured for both treatment groups. Adverse effects were recorded at each follow up appointment. Laboratory investigations were completed monthly and included a complete blood count (CBC), lipid profile including total cholesterol and triglyceride levels, ALT, TSH, bilirubin, and $β$ -HCG for female participants of childbearing age.

Wilcoxon’s rank sum test was used to compare changes in PGA and DLQI scores within and between groups. Fisher’s exact test was used to compare the frequency of adverse effects between the two treatment groups. All statistical analyses were conducted in RStudio 1.4 (Boston, MA) using one-tailed p-values with significance determined a priori at $\propto$ <.05.

Results

A total of n = 64 participants were included with a mean age of 41.25 years (range, 22-62 years). More than half (57.8%) of the participants were male. The most common skin type was Fitzpatrick 2 (n = 30/64, 46.9%). Mean duration of disease before study inception was 3.14 years (range, 1-9 years). The majority of participants had HHD (n = 45/64, 70.3%), followed by DHE (n = 14/64, 21.9%) and FTD (n = 5/64, 7.8%). Just 18.8% (n = 12/64) of participants had undergone patch-testing and 12.5% (n = 8/64) had a previous skin biopsy.

Thirty-three participants received LDA-UVB and thirty-one participants received HDA. Baseline demographics and clinical characteristics of the cohorts were comparable and are summarized in Table 1.

Table 1

Baseline Demographics and Characteristics of the Study Population.

Variable	ALL (n = 64)	LDA-UVB (n = 33)	HDA (n = 31)
Mean age (range)	41.25 (22-62)	42.03 (22-62)	40.42 (24-58)
% Male	57.8%	54.5%	61.3%
Fitzpatrick Skin Types
1	8 (12.5%)	6 (18.2%)	2 (6.5%)
2	30 (46.9%)	11 (33.3%)	19 (61.3%)
3	14 (21.9%)	9 (27.3%)	5 (16.1%)
4	8 (12.5%)	4 (12.1%)	4 (12.9%)
5	4 (6.2%)	3 (9.1%)	1 (3.2%)
Diagnoses
HHD	45 (70.3%)	23(69.7%)	22 (71.0%)
DHE	14 (21.9%)	7 (21.2%)	7 (22.6%)
FTD	5 (7.8%)	3 (9.1%)	2 (6.4%)
Mean duration of disease in years (range)	3.14 (1-9)	3.03 (1-7)	3.26 (1-9)
Initial PGA scores (%)
3	20 (31.3%)	13 (39.4%)	7 (22.6%)
4	44(68.7%)	20 (60.6%)	24 (77.4%)
Median initial DLQI scores (range)	13 (7, 23)	13 (7, 23)	14 (9, 23)

Abbreviations: DHE: dyshidrotic hand eczema; DLQI: dermatology life quality index; FTD: fingertip dermatitis; HDA: high dose alitretinoin; HHD: hyperkeratotic hand dermatitis; LDA-UVB: low dose alitretinoin with narrow band UVB therapy; PGA: physician global assessment.

Both cohorts had statistically significant improvements in disease severity from baseline after 16 weeks ( Table 2 ). The initial mean PGA score for the LDA-UVB cohort was 3.61 (range, 3-4), and the final PGA score was 1.36 (range, 0-4) (P < .0001). Among the HDA cohort, the initial mean PGA score was 3.77 (range 3-4) and the final mean PGA score was 1.77 (range 0-4), (P < .0001). Significantly more participants in the LDA-UVB group (n = 21/33, 63.6%) achieved a PGA rating of “clear” or “almost clear” hands compared to the HDA group after 16 weeks (n = 12/31, 38.7%; P < .05).

Table 2

Results at 16 weeks.

Variable	LDA-UVB (n = 33)	HDA cohort (n = 31)	P value
Mean final PGA score (range)	1.36 (0, 4)	1.77 (range 0-4)	0.09
Final PGA scores of 0-1 (%)	21 (63.6%)	12 (38.7%)	0.04
Median final DLQI score (range)	7 (1, 11)	8 (2, 15)	0.01
Number (%) reporting >50% reduction in final DLQI score	15 (45.4%)	12 (48.4%)	0.11
Adverse effect of any type (%)	13 (39.4%)	23 (74.2%)	4.8 × 10^–5
Headache (%)	2 (6.1%)	11 (35.5%)	4.0 × 10^–3
Elevated cholesterol (%)	2 (6.1%)	8 (25.8%)	0.03
Dry lips (%)	2 (6.1%)	8 (25.8%)	0.03

Abbreviations: DLQI, dermatology life quality index; HDA, high dose alitretinoin; LDA-UVB , low-dose alitretinoin with narrowband UVB therapy; PGA, physician’s global assessment.

Wilcoxon rank sum test was used to compare continuous or nominal variables and Fisher’s exact test used to compare categorical data between the LDA-UVB and HDA groups.

Both cohorts reported statistically significant improvements in their QOL at 16 weeks (Table 2). The initial median DLQI score for the LDA-UVB cohort was 13 (range, 7-23), and the final medial DLQI score was 7 (range, 1-11) (P < .0001). The HDA cohort reported an initial median DLQI score of 14 (range, 9-23), and a final median DLQI score of 8 (range, 2-15) (P < .0001). The proportion of participants who experienced an improvement in their QOL (50% or greater reduction in their final DLQI score) at 16 weeks was comparable between cohorts; 45.4% (n = 15/33) achieved this outcome in the LDA-UVB group compared to 48.4% (n = 15/31) in the HDA group (P > .05). The proportion of participants who reported their CHD had either “no” or a “small” impact on their QOL at 16 weeks was similar between cohorts (LDA-UVB n = 15/33, 45.4%; HDA n = 11/31, 35.4%, P > .05).

Adverse effects of any type were significantly more prevalent in the HDA cohort compared to the LDA-UVB cohort (P < .0001). Within the HDA cohort, 74.2% (n = 23/31) experienced at least one adverse effect compared to 39.4% (n = 13/33) of the LDA-UVB cohort. Analysis of individual adverse effects revealed significantly more participants in the HDA group had headaches (n = 11/31,35.5%), elevated cholesterol (n = 8/31, 25.8%), and dry lips (n = 8/31, 25.8%) compared to the LDA-UVB group. No participants in either cohort discontinued treatment due to adverse effects and no participants experienced serious adverse medical events. The combination of low dose oral alitretinoin with NB-UVB therapy was well tolerated in this studied cohort.

Discussion

This study compared LDA-UVB to HDA for patients with CHD refractory to topical corticosteroids in a real-world setting. Participants who received LDA-UVB for 16 weeks had significantly better outcomes in skin clearance and fewer adverse effects compared to participants who received HDA. These findings suggest that the combination of low dose oral alitretinoin with phototherapy is well tolerated and may produce better results with fewer adverse effects than the recommended higher doses of oral alitretinoin alone for CHD.

Re-UV has been a treatment option for moderate to severe plaque psoriasis for almost 4 decades²⁴ and has demonstrated superior results than either monotherapy in treating psoriasis and cutaneous T-cell lymphoma (CTCL).^{24

-33} Several double-blind randomized controlled trials determined that Re-UV combination therapy was more effective than placebo-UV or UV alone at clearing psoriasis.^26

-30 Participants who received Re-UV had significantly greater response rates and lower cumulative UV energies.^27,29 These pivotal studies confirmed the synergistic effects of Re-UV. Retinoids thin the stratum corneum and enhance UV penetration, making the skin more susceptible to UV radiation and inducing a faster response.³⁴ Thus, lower cumulative dosages of UV light may be effective, and the long-term carcinogenic risk of UV treatment may be reduced. Meanwhile, concurrent phototherapy permits lower dosages of retinoids to be effective and minimizes their dose-dependent adverse effects.^27,29 Studies of Re-UV combination in patients with CTCL found it prolonged remission, required fewer UV sessions and lower UV doses to attain remission, and had similar response rates compared to PUVA alone.^31
-33 Given the promising results of Re-UV in other conditions, the combination may be a welcome addition to the armamentarium for steroid refractory CHD.

The strengths of this study include its real-world setting and interesting results of statistically significant differences in clinical outcomes and adverse effect profiles between cohorts. However, the study was limited by its relatively small sample size and retrospective design. Treatment duration was only 16 weeks, and results of further follow-up were not reported. A potential challenge of the LDA-UVB treatment was that it required participants to return to the dermatology clinic three times weekly for their phototherapy treatment. This treatment burden may partially explain why our study did not find a significant difference in DLQI scores after treatment between cohorts. Larger prospective studies that compare low dose oral alitretinoin with NB-UVB therapy to high dose oral alitretinoin, NB-UVB therapy alone, or oral placebo with NB-UVB therapy are needed to further evaluate the effects of Re-UV in CHD and to test for differences in cumulative UV exposure.

In conclusion, low dose oral alitretinoin (10 mg) combined with NB-UVB three times weekly provided higher skin clearance rates and fewer adverse effects compared to high dose oral alitretinoin (30 mg daily) in patients with CHD refractory to topical corticosteroids. To the best of our knowledge, this is the first investigation of Re-UV combination therapy in CHD refractory to topical corticosteroid therapy. Current guidelines for the treatment of hand dermatitis do not mention Re-UV therapy.^1,5,35,36 A recent Cochrane Review of all therapies for hand dermatitis did not find a single study that investigated Re-UV therapy.²³ A search of the online databases OVID Medline 1946 to present, Embase 1974 to present, the Cochrane Central Register of Controlled Trials (CENTRAL), and the Web of Science Core Collection 1976 to present did not retrieve any proposals or completed studies that assessed Re-UV in CHD.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

E. Dimitra Bednar

Mohannad Abu-Hilal

References

Lynde

Guenther

Diepgen

et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284.doi:10.2310/7750.2010.09094

21084020

Ruzicka

Lynde

CW.

Jemec

GBE

et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158(4):808-817.doi:10.1111/j.1365-2133.2008.08487.x

18294310

Fowler

JF.

Graff

Hamedani

. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. J Drugs Dermatol. 2014;13(10):1198-1204.25607554

Thyssen

JP.

Johansen

JD.

Linneberg

Menné

. The epidemiology of hand eczema in the general population--prevalence and main findings. Contact Dermatitis. 2010;62(2):75-87.doi:10.1111/j.1600-0536.2009.01669.x

20136890

Diepgen

TL.

Andersen

KE.

Chosidow

et al. Guidelines for diagnosis, prevention and treatment of hand eczema - short version. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2015;13(1):77-84.doi:10.1111/ddg.12510

Boehm

Schmid-Ott

Finkeldey

et al. Anxiety, depression and impaired health-related quality of life in patients with occupational hand eczema. Contact Dermatitis. 2012;67(4):184-192.doi:10.1111/j.1600-0536.2012.02062.x

22564098

Kouris

Armyra

Christodoulou

et al. Quality of life, anxiety, depression and obsessive-compulsive tendencies in patients with chronic hand eczema. Contact Dermatitis. 2015;72(6):367-370.doi:10.1111/cod.12366

25693684

Bissonnette

Diepgen

TL.

Elsner

et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24(Suppl. 3):1-20.doi:10.1111/j.1468-3083.2010.03615.x

20443999

Bissonnette

Worm

Gerlach

et al. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. Br J Dermatol. 2010;162(2):420-426.doi:10.1111/j.1365-2133.2009.09572.x

19906075

10.

Crane

MM.

Webb

DJ.

Watson

Cunliffe

English

. Hand eczema and steroid-refractory chronic hand eczema in general practice: prevalence and initial treatment. Br J Dermatol. 2017;176(4):955-964.doi:10.1111/bjd.14974

11.

Health Canada . Product Information: TOCTINO 30 mg. Published [2021 March 15]. 2021 March 26. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=82322

12.

Diepgen

TL.

Pfarr

Zimmermann

. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol. 2012;92(3):251-255.doi:10.2340/00015555-1256

22281779

13.

Augustin

Thaçi

Kamps

. Impact on quality of life of alitretinoin in severe chronic hand eczema: FUGETTA real-world study. J Dtsch Dermatol Ges. 2016;14(12):1261-1270.doi:10.1111/ddg.12870

27992140

14.

Thaçi

Augustin

Westermayer

Kamps

Hennig

. Effectiveness of alitretinoin in severe chronic hand eczema: passion, a real-world observational study. J Dermatolog Treat. 2016;27(6):577-583.doi:10.1080/09546634.2016.1227422

27618281

15.

Stiefel . Product monograph: Toctino® (alitretinoin): Soft capsule 10 mg and 30 mg. Published [2019 June 25]. 2021 March 07. https://ca.gsk.com/media/1352344/toctino-product-monograph.pdf

16.

Silvestre Salvador

JF.

Heras Mendaza

Hervella Garcés

et al. Guidelines for the diagnosis, treatment, and prevention of hand eczema. Actas Dermosifiliogr. 2020;111(1):26-40.doi:10.1016/j.ad.2019.04.005

32197684

17.

Grattan

CE.

Carmichael

AJ.

Shuttleworth

GJ.

Foulds

. Comparison of topical PUVA with UVA for chronic vesicular hand eczema. Acta Derm Venereol. 1991;71(2):118-122.1675518

18.

Polderman

MCA.

Govaert

JCM.

Le Cessie

Pavel

. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol. 2003;28(6):584-587.doi:10.1046/j.1365-2230.2003.01378.x

14616819

19.

Rosén

Mobacken

Swanbeck

. Chronic eczematous dermatitis of the hands: a comparison of PUVA and UVB treatment. Acta Derm Venereol. 1987;67(1):48-54.2436414

20.

Sjövall

Christensen

. Local and systemic effect of UVB irradiation in patients with chronic hand eczema. Acta Derm Venereol. 1987;67(6):538-541.2451385

21.

Sezer

Etikan

. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed. 2007;23(1):10-14.doi:10.1111/j.1600-0781.2007.00258.x

17254029

22.

Brass

Fouweather

Stocken

et al. An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen-ultraviolet a with localized narrowband ultraviolet B for the treatment of palmar hand eczema. Br J Dermatol. 2018;179(1):63-71.doi:10.1111/bjd.16238

23.

Christoffers

WA.

Coenraads

P-J.

Svensson

et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019;4:CD004055.doi:10.1002/14651858.CD004055.pub2

31025714

24.

Lebwohl

Drake

Menter

et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 2001;45(4):544-553.doi:10.1067/mjd.2001.116347

11568745

25.

Olsen

EA.

Hodak

Anderson

et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States cutaneous lymphoma Consortium. J Am Acad Dermatol. 2016;74(1):27-58.doi:10.1016/j.jaad.2015.09.033

26547257

26.

Fritsch

PO.

Hönigsmann

Jaschke

Wolff

. Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative. J Invest Dermatol. 1978;70(4):178-182.doi:10.1111/1523-1747.ep12541294

641368

27.

Ruzicka

Sommerburg

Braun-Falco

et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol. 1990;126(4):482-486.doi:10.1001/archderm.1990.01670280066012

2138875

28.

Saurat

JH.

Geiger

JM.

Amblard

et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica. 1988;177(4):218-224.doi:10.1159/000248567

2976000

29.

Tanew

Guggenbichler

Hönigsmann

Geiger

JM.

Fritsch

. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991;25(4):682-684.doi:10.1016/0190-9622(91)70253-X

1838750

30.

Parker

Coburn

Lawrence

Marks

Shuster

. A randomized double-blind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis. Br J Dermatol. 1984;110(2):215-220.doi:10.1111/j.1365-2133.1984.tb07470.x

6365147

31.

Singh

Lebwohl

. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol. 2004;51(4):570-573.doi:10.1016/j.jaad.2003.05.010

15389192

32.

Thomsen

Hammar

Molin

Volden

. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian mycosis fungoides group. Acta Derm Venereol. 1989;69(6):536-538.2575334

33.

Whittaker

Ortiz

Dummer

et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC cutaneous lymphoma Task force phase III randomized clinical trial 21011 (NCT00). Br J Dermatol. 2012;167(3):678-687.doi:10.1111/j.1365-2133.2012.11156.x

22924950

34.

Lim

. Abnormal responses to ultraviolet radiation: Photosensitivity induced by exogenous agents. In: Goldsmith

Katz

SI.

Gilchrest

BA.

, eds. Fitzpatrick’s Dermatology in General Medicine. 8th ed. McGraw-Hill; 2012:1066-1074.

35.

Menné

Johansen

Sommerlund

Veien

Danish Contact Dermatitis Group . Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema. Contact Dermatitis. 2011;65(1):3-12.doi:10.1111/j.1600-0536.2011.01915.x

21658053

36.

Diepgen

TL.

Elsner

Schliemann

et al. Guideline on the management of hand eczema ICD-10 code: L20. L23. L24. L25. L30. J Dtsch Dermatol Ges. 2009;7(4):S1-S15.doi:10.1111/j.1610-0379.2009.07061.x

19522920

Low Dose Oral Alitretinoin With Narrowband Ultraviolet B Therapy for Chronic Hand Dermatitis

Abstract

Background

Objective

Methods

Results

Conclusions

Keywords

Introduction

Methods & Patients

Study Design

Participants

Interventions

Outcome Measures and Statistical Analyses

Results

Discussion

Footnotes

Declaration of Conflicting Interests

Funding

ORCID iDs

References